Repare Therapeutics (RPTX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Platform and technology overview

• Synthetic lethality is the core scientific approach, targeting gene alterations in aggressive tumors to identify synergistic drug targets.

• Four clinical programs have been developed around synthetic lethality, with compelling preclinical and clinical data supporting the approach.

• Focus is on DNA damage repair mechanisms, with key programs like lunresertib and PLK4 targeting specific genetic alterations.

• Patient selection is driven by genetic markers, ensuring precision oncology and higher likelihood of response.

• Animal studies, especially in pediatric neuroblastoma, have shown promising results, guiding clinical development.

Collaborations and diagnostics

• Partnership with Foundation Medicine Inc. supports development and validation of companion diagnostics for patient selection.

• Next-generation sequencing is expected to streamline future patient identification.

• Foundation Medicine will play a key role as lunresertib advances.

Clinical program and trial updates

• Lunresertib is the lead program, with key data from its combination with camonsertib expected late in Q4, post-medical meetings.

• Phase I data for lunresertib plus FOLFIRI in colorectal cancer with FBXW7 alterations showed promising signals.

• The MYTHIC trial is testing lunresertib plus camonsertib in platinum-resistant ovarian and endometrial cancer, with data expected late Q4.

• Initial MYTHIC data showed a 50% response rate in a small gynecological cancer cohort at the recommended dose.

• Anemia was an early challenge but has been managed with dose holidays, resulting in a favorable safety profile.